Just learned about this.
Salem, New Hampshire, March 31, 2010 – AgaMatrix, Inc. and
sanofi-aventis (EURONEXT: SAN and NYSE: SNY) today announced that they
have signed a long-term agreement for the development, supply and
commercialization of blood glucose monitoring (BGM) solutions. Under
the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop
innovative solutions in diabetes management that incorporate
AgaMatrix’s WaveSense™ technology. Sanofi-aventis will commercialize
through its Global Diabetes Division such integrated solutions for
patients with diabetes, along with current sanofi-aventis insulins and
delivery devices. Sanofi-aventis’ insulin and device portfolio include
Lantus®, a basal insulin that is the number one insulin prescribed
worldwide, and Apidra®, a leading fast-acting insulin, plus its
easy-to-use delivery pens SoloSTAR® and ClikSTAR®.